Biosynthesis Inhibitors or Anti-Androgens: Which One Should I Choose?

Posted by Lawrence I. Karsh, MD | Aug 2016

Dr. Lawrence I. Karsh spoke at the 21st annual Scottsdale Prostate Cancer Symposium 2016 on Saturday, March 12, 2016 on “Biosynthesis Inhibitors or Anti-Androgens: Which One Should I Choose?”.

Keywords: prostate cancer, Abiraterone, Enzalutamide, hormone therapies, CRPC

How to cite: Karsh, Lawrence I. “Biosynthesis Inhibitors or Anti-Androgens: Which One Should I Choose?” Grand Rounds in Urology. March 12, 2016. Accessed Apr 2024. https://grandroundsinurology.com/prostate-cancer-lawrence-karsh-biosynthesis-inhibitors-or-anti-androgens-which-one-should-i-choose/.

About The Author

Lawrence I. Karsh, MD

Lawrence I. Karsh, MD, is a Co-Founder of The Urology Center of Colorado, where he serves as an attending urologist and Director of Research & Co-Chairman of the Advanced Therapeutic Clinic. He is a certified principal investigator, and has been the principal investigator on over 250 clinical trials. He has authored a number of peer-reviewed publications and serves on the editorial boards for Oncology Live, Urologists in Cancer Care, and Bladder Cancer. He is a fellow of the American College of Surgeons, and an active member of the AUA, SUO, ASCO, SWOG, ACS, and the Denver Academy of Surgeons. He has served on the bladder cancer subcommittee and the advisory board for the SUO Clinical Trials Consortium and is a member of the Bladder Cancer Advocacy Network (BCAN) Think Tank. Dr. Karsh completed his general surgery training at the University of Colorado Health Sciences Center (UCHSC) and his urology residency at Brigham and Women’s Hospital/Harvard Medical School. He is an Associate Clinical Professor of Surgery at UCHSC. Dr. Karsh participates in many advisory boards for new drug development. He lectures and teaches at scientific meetings throughout the country.